76 results
8-K
EX-99.1
ANAB
AnaptysBio Inc
11 Mar 24
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:19pm
ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks
8-K
EX-99.1
ANAB
AnaptysBio Inc
5 Jan 24
Results of Operations and Financial Condition
4:09pm
activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under
8-K
EX-99.1
sbg8h735ey9eoi53 kqg
27 Nov 23
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-99.1
ksdr6c12n14x3koel6z
2 Nov 23
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
EX-99.1
sk8thx
10 Oct 23
Regulation FD Disclosure
9:01am
8-K
EX-99.1
zuscksmwoloo mfrme1
7 Aug 23
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
EX-99.1
h216kknojs73itl5f0o
11 May 23
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
4:17pm
PRE 14A
pzh0a
14 Apr 23
Preliminary proxy
4:15pm
8-K
EX-99.1
y8t1k iu1n3y5tnr
8 Nov 22
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
4:08pm
8-K
EX-99.2
h3ex2dq43h3 2lb1
8 Nov 22
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
4:08pm
8-K
EX-99.1
jwyntv
12 Sep 22
Entry into a Material Definitive Agreement
7:32am
8-K
EX-99.1
jla1o
31 Aug 22
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
4:19pm
8-K
EX-99.1
c3sdmj1j 6cycsyxrlq
8 Aug 22
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
4:21pm
8-K
EX-99.1
24jpmwo690dnvhdi94h
4 May 22
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
4:19pm